As Biogen Inc., Merck & Co. Inc. and Eli Lilly and Co. race to the finish line with their Alzheimer’s disease drugs that are in phase III development, two companies – Neuro-Bio Ltd. and Ironwood Pharmaceuticals Inc. – are just lacing up their shoes. Read More
Feb. 29, 2016, marked the ninth year that the international rare disease community celebrated Rare Disease Day, which is designed to focus global attention on the need for therapies to treat patients suffering from devastating rare diseases that have, as yet, no effective treatments and limited research and funding to change the situation. Read More
